A NASDAQ-listed company which acquires, develops and commercializes promising drugs and technologies is seeking asset partnerships. The firm provides partners with committed investment capital, experienced start-up management, world-class scientific expertise, and shared facilities. The firm does not make typical equity investments, but rather is open to a variety of deal structures to acquire or co-develop assets, including traditional milestone-based licensing deals, joint ventures, option agreements and equity arrangements (no less than 50% equity stake).
The company focuses primarily on therapeutic opportunities, but will consider diagnostic and medical devices that are based on compelling science. Current areas of interest include dermatology, rare diseases, oncology, acute care, and specialist products (eg. in hepatology, GI, women’s health).
The firm has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment